Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by plasmodium vivax

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1468-1475

  Lim, Hyeong Seok ^a   Im, Jeong Soo ^b   Cho, Joo Youn ^c   Bae, Kyun Seop ^a   Klein, Terry A ^d   Yeom, Joon Sup ^e   Kim, Tae Seon ^b   Choi, Jae Seon ^b   Jang, In Jin ^c   Park, Jae Won ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Force Health Protection   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE SULFATE;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALARIA; MALE; PLASMODIUM VINCKEI; PREDICTION; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE; TREATMENT FAILURE;

ADULT; ANIMALS; ANTIMALARIALS; AREA UNDER CURVE; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALARIA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PLASMODIUM VIVAX;

EID: 65649150048     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00339-08     Document Type: Article

References (31)

1. Baird, J. K. 2004. Chloroquine resistance ia Plasmodium vivax. Antimicrob. Agents Chemother. 48:4075-4083. (Pubitemid 39434858)
2. Blauer, G., and M. Akkawi. 1995. B-hematin. Biochem. MoI. Biol. Int. 35:231-235. (Pubitemid 26177790)
3. Carmichael, S. J., Charles, B., and S. E. Tett. 2003. Population pharmaco-kinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther. Drug Monit. 25:671-681. (Pubitemid 37499301)
4. Chen, M. L. 2006. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 45:957-964. (Pubitemid 44436000)
5. Ducharme, J., H. Fieger, M. P. Ducharme, S. K. Khalil, and I. W. Wainer. 1995. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br. J. Clin. Pharmacol. 40:127-133. (Pubitemid 26201440)
6. Easterbrook, M. 1999. Detection and prevention of maculopathy associated with antimalarial agents. Int. Ophthalmol. Clin. 39:49-57. (Pubitemid 29222656)
7. Edwards, G., S. Looareewuwan, A. J. Davis, Y. Wattanagoon, R. E. Phillips, and D. A. Warrell. 1988. Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects with Plasmodium vivax malaria. Br. J. Clin. Pharmacol. 22:477-485. (Pubitemid 18151577)
8. Galinski, M. R., and J. W. Barnwell. 1996. Plasmodium vivax: merozoite invasion of reticulocytes and considerations for malaria vaccine develop-ment. Parasitol. Today 12:20-29. (Pubitemid 26029528)
9. Gustaffson, L. L., L. Rombo, G. Alvan, A. Bjorkman, M. Lind, and O. Walker. 1983. On the question of dose-dependent chloroquine elimination of a single dose. Clin. Pharmacol. Ther. 34:383-385.
10. Haberkorn, A., H. P. Kraft, and G. Blaschke. 1979. Antimalarial activity of the optical isomers of chloroquine diphosphate. Tropenmed. Parasitol. 30: 308-312. (Pubitemid 10245042)
11. Hankey, D. D., R. Jones, G. R. Coatney, A. S. Alving, W. G. Coker, P. L. Garrison, and W. N. Donovan. 1953. Korean vivax malaria. I. Natural history and response to chloroquine. Am. J. Trop. Med. Hyg. 2:958-969.
12. Krishna, S., and N. J. White. 1996. Pharmacokinetics of quinine, chloro-quine and amodiaquine. Clin. Pharmacokinet. 30:263-299.
13. McChesney, E. W., W. D. Conway, W. F. Banks, J. E. Rogers, Jr., and J. M. Shekosky. 1966. Studies of the metabolism of some compounds of the 4-ami-no-7-chloroquinoline series. J. Pharmacol. Exp. Ther. 151:482-493.
14. McLachlan, A. J., S. E. Tett, D. J. Cutler, and R. O. Day. 1993. Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid ar-thritis following multiple doses of the racemate. Br. J. Clin. Pharmacol. 36:78-81. (Pubitemid 23205319)
15. Murphy, G. S., H. Basri, Purnomo, E. M. Andersen, M. J. Bangs, D. L. Mount, J. Gorden, A. A. LaI, A. R. Purwokusumo, S. Harjosuwamo, K. Sorensen, and S. L. Hoffman. 1993. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 341:96-100. (Pubitemid 23028126)
16. Paik, Y. H., H. I. Ree, and J. C. Shim. 1988. Malaria in Korea. Jpn. J. Exp. Med. 58:55-66.
17. Park, J. W., T. A. Klein, H. C. Lee, L. A. Pacha, S. H. Ryu, J. S. Yeom, S. H. Moon, T. S. Kim, J. Y. Chai, M. D. Oh, and K. W. Choe. 203. Vivax malaria: a continuing health threat to the Republic of Korea. Am. J. Trop. Med. Hyg. 69:159-167.
18. Rieckmann, K. H., D. R. Davis, and D. C. Hutton. 1989. Plasmodium vivax resistance to chloroquine? Lancet ii: 1183-1184. (Pubitemid 19275451)
19. The R Project for Statistical Computing. 2008. http://www.r-project.org/. Accessed 23 January 2008.
20. Sachs, J., and P. Malaney. 2002. The economic and social burden of malaria. Nature 415:680-685. (Pubitemid 34136401)
21. Slater, A. F. G., and A. Cerami. 1992. Inhibition by chloroquine of a novel haem polymerase activity in malaria trophozoites. Nature 355:167-169.
22. Tatami, S., N. Yamamura, A. Sarashina, C. L. Yong, T. Igarashi, and Y. Tanigawara. 2004. Pharmacokinetic comparison of an angiotensin II recep-tor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. Drug Metab. Pharmacokinet. 19:15-23.
23. ter Kuile, F. O., N. J. White, P. Holloway, G. Pasvol, and S. Krishna. 1993. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of antimalarials used for the treatment of severe malaria. Exp. Parasitol. 76:85-95. (Pubitemid 23197907)
24. Tett, S. E., and D. J. Cutler. 1987. Apparent dose dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times. Eur. J. Clin. Pharmacol. 31:729-731. (Pubitemid 17021008)
25. Tett, S. E., R. O. Day, and D. J. Cutler. 1993. Concentration-effect relation-ship of hydroxychloroquine in rheumatoid arthritis-a cross sectional study. J. Rheumatol. 20:1874-1879. (Pubitemid 24031590)
26. Titus, E. O.1989. Recent developments in the understanding of the pharmacoki-netics and mechanism of action of chloroquine. Ther. Drug Monit. 11:369-379. (Pubitemid 19157194)
27. WFN Bootstrap. 2008. http://wfn.sourceforge.net/wfnbs.htm. Accessed 3 Jan-uary 2008.
28. World Health Organization. 1981. Synopsis of the world malaria situation in 1979. WkIy. Epidemiol. Rec. 56:145-149.
29. Yeom, J. S., S. H. Ryu, S. Oh, D. H. Choi, K. J. Song, Y. H. Oh, J. H. Lee, Y. A. Kim, S. Y. Ahn, H. Y. Yang, J. E. Cha, and J. W. Park. 2005. Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea Army. J. Korean Med. Sei. 20:707-712. (Pubitemid 41587225)
30. Yeom, J. S., S. H. Ryu, S. Oh, W. J. Lee, T. S. Kim, K. H. Kim, Y. A. Kim, S. Y. Ahn, J. E. Cha, and J. W. Park. 2005. Status of Plasmodium vivax malaria in the Republic of Korea during 2001-2003. Am. J. Trop. Med. Hyg. 73:604-608. (Pubitemid 41324269)
31. Yeom, J. S., T. S. Kim, J. B. Sim, J. S. Barn, H. J. Kim, Y. A. Kim, S. Y. Ahn, M. Y. Shin, J. A. Yoo, and J. W. Park. 2007. Plasmodium vivax malaria in the Republic of Korea during 2004-2005: changing patterns of infection. Am. J. Trop. Med. Hyg. 76:865-868.